Alnylam Pharmaceuticals (ALNY) Short-term Investments (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Short-term Investments came in at $1.6 billion in Q2 2026, down 8.26% YoY from $1.7 billion in Q2 2025, and up 23.21% on a QoQ basis from $1.3 billion in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Short-term Investments (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Short-term Investments data on file, last reported at $1.6 billion in Q2 2026.
- Quarterly Short-term Investments fell 8.26% year-over-year to $1.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (down 8.26% YoY) and the FY2025 annual result came in at $1.3 billion, down 27.25% from the prior year.
- Short-term Investments advanced to $1.6 billion in Q2 2026, from $1.3 billion in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $1.7 billion in Q2 2025 to a low of $1.2 billion in Q3 2022.
- A 5-year average of $1.5 billion and a median of $1.6 billion in 2022 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2022 — Short-term Investments surged 36.52% — and 2025, when it fell 27.25%.
- Tracing ALNY's Short-term Investments over 5 years: stood at $1.3 billion in 2022, then increased by 24.47% to $1.6 billion in 2023, then advanced by 6.46% to $1.7 billion in 2024, then slipped by 27.25% to $1.3 billion in 2025, then increased by 27.86% to $1.6 billion in 2026.
- The last three Short-term Investments figures came in at $1.6 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.60 Bn |
| Mar 31, 2026 | 1.30 Bn |
| Dec 31, 2025 | 1.25 Bn |
| Mar 31, 2025 | 1.61 Bn |
| Dec 31, 2024 | 8.16 Mn |
| Sep 30, 2024 | 8.32 Mn |
| Jun 30, 2024 | 1.65 Bn |
| Mar 31, 2024 | 11.26 Mn |
| Dec 31, 2023 | 1.62 Bn |
| Sep 30, 2023 | 10.41 Mn |
| Jun 30, 2023 | 27.26 Mn |
| Mar 31, 2023 | 25.86 Mn |
| Dec 31, 2022 | 1.30 Bn |
| Sep 30, 2022 | 23.05 Mn |
| Jun 30, 2022 | 30.90 Mn |
| Mar 31, 2022 | 1.67 Bn |
| Dec 31, 2021 | 66.97 Mn |
| Sep 30, 2021 | 72.55 Mn |
| Jun 30, 2021 | 52.53 Mn |
| Mar 31, 2021 | 56.97 Mn |